Maxim raised the firm’s price target on Palisade Bio (PALI) to $8 from $2 and keeps a Buy rating on the shares, citing lower risk as the firm contends that the company’s recent financing supports trials for ‘2108 and potential approval.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PALI: